Michael Neuss Archives
Jan. 27, 2022—The Vanderbilt internal medicine residency handbook has long been a resource that is easy, enjoyable and helpful for residents to use in clinical practice.
Jun. 12, 2018—After successfully leading Vanderbilt-Ingram Cancer Center (VICC) through years of growth in patient volumes and enhanced care options, Michael Neuss, MD, Chief Medical Officer of the VICC Clinical Enterprise, is retiring as CMO. Neuss will be succeeded by Madan Jagasia, MBBS, MSCI, MMHC, who has been named to the George and Beverly Rawlings Directorship and is section chief, Hematology and Stem Cell Transplant and director of the Outpatient Stem Cell Clinic.
Apr. 2, 2015—The death rates for most forms of cancer continue to decline at a modest pace among men, women and children in the United States, according to the Annual Report to the Nation on the Status of Cancer 1975 – 2011.
Oct. 2, 2014—The Vanderbilt Cardio-Oncology program has fostered a special collaborative relationship combining the expertise of cardiologists and oncologists to understand the effects of cancer therapy on the heart. This type of collaboration is now helping to define the cardiovascular health of more than 14 million cancer survivors in the United States.
Jun. 19, 2014—New Vanderbilt research suggests patients with advanced melanoma — the most deadly form of skin cancer — could safely benefit from a combination of immunotherapy and targeted therapies aimed at specific gene mutations.
Aug. 16, 2012—Vanderbilt-Ingram Cancer Center (VICC) has opened a new outpatient cancer clinic on the NorthCrest Medical Center campus in Springfield, Tenn., to bring high quality care to patients in Middle Tennessee and Southern Kentucky.
Feb. 2, 2012—Watch video of Dr. Michael Neuss speaking about the fight against cancer. Neuss spoke Feb. 1 as part of the Osher Lifelong Learning class, “Medical Advances.” The course is presented by faculty of the Vanderbilt University Medical Center and focuses on what the future of medicine holds. Physicians are now able to use a patient’s DNA...